Loading...
Loading...
- Cooper Companies Inc COO reported that Q4 sales increased 11% Y/Y to $759.1 million, beating the consensus of $747.85 million.
- Q4 adjusted EPS of $3.28 increased 4% Y/Y, missing the consensus of $3.37.
- Adjusted gross margin compressed to 67% from 68% a year ago, driven primarily by currency.
- Adjusted operating margin was 25%, down from 27% last year, driven primarily by investment activity.
- CooperVision (CVI) Revenue reached $564.8 million, up 12% Y/Y, up 11% in constant currency.
- The company achieved CooperSurgical (CSI) revenue of $194.3 million, +11% on a reported and constant currency basis.
- Cash provided by operations $174.5 million offset by capital expenditures $65.0 million resulted in free cash flow of $109.5 million. Net debt outstanding at quarter-end was $1.38 billion.
- Guidance: Cooper Companies expects FY22 sales of $3.032 billion - $3.09 billion (+6% to 8% in constant currency), compared to a consensus of $3.09 billion.
- The sales outlook includes CVI revenue of $2.225 billion - $2.267 billion and CSI revenue of $807 million - $823 million.
- Cooper Companies sees adjusted EPS of $13.60 - $14.00 (consensus of $14.49).
- Related: CooperSurgical Expands Fertility, Labor & Delivery With $1.6B Acquisition Deal.
- Price Action: COO shares are up 2.51% at $387.43 during the market session on the last check Friday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in